Frazier Life Sciences Management, L.P. holds a focused book of 38 stocks worth $3.9B as of Q1 2026 (disclosed May 15, 2026, a ~45-day 13F lag). This quarter they opened Biocryst Pharmaceuticals Inc and trimmed Bridgebio Pharma Inc. Their largest long position is Mirum Pharmaceuticals Inc at 18% of the equity book.
The public view is the crawlable proof. The same sourced dataset is available through REST and MCP for agents, research scripts, and back-office tools.
This fund page is the Follow view. The Build view lets your agent pull holdings, quarter changes, overlap, and source filings through API or MCP.
curl -H "Authorization: Bearer YOUR_API_KEY" \ "https://arkolith.com/api/v1/funds/1892134/holdings"
Use Arkolith to show Frazier Life Sciences Management, L.P.'s latest holdings, largest changes, and filing provenance.
Top-heavy: focused book
Share of the disclosed book in its largest positions. A higher top-5 share means a more concentrated, higher-conviction portfolio.
99% mapped to company sectors
Direct operating-company sectors from our SIC-based security master. ETF/fund and unclassified holdings stay visible separately; this is not ETF look-through exposure.
Estimated $ traded · quarter-end prices, no cost basis
Bars show each stock's share of the portfolio. Click a row for its position history.
| # | Security | Value | Shares | % Port | Last move | History |
|---|---|---|---|---|---|---|
| 1 | Mirum Pharmaceuticals Inc COM | $709.4M | 7.68M | 18.3% | ▲+13% Added · +885K sh | |
| 2 | Newamsterdam Pharma Company ORDINARY SHARES | $542.4M | 16.94M | 14.0% | —Held | |
| 3 | Erasca Inc COM | $399.2M | 24.68M | 10.3% | ▲+8.6% Added · +1.9M sh | |
| 4 | Bridgebio Pharma Inc COM | $256.1M | 3.45M | 6.6% | ▼−2.7% Reduced · −97K sh | |
| 5 | Arcutis Biotherapeutics Inc COM | $232.6M | 9.87M | 6.0% | —Held | |
| 6 | MBX Biosciences Inc COM | $198.6M | 6.65M | 5.1% | —Held | |
| 7 | Phathom Pharmaceuticals Inc COM | $138.5M | 12.47M | 3.6% | —Held | |
| 8 | Maze Therapeutics Inc COM | $136.3M | 4.57M | 3.5% | —Held | |
| 9 | Krystal Biotech Inc COM | $124.3M | 481.3K | 3.2% | ▼−1.5% Reduced · −7K sh | |
| 10 | Trevi Therapeutics Inc COM | $118.6M | 9.94M | 3.1% | ▼−3.1% Reduced · −320K sh | |
| 11 | Palvella Therapeutics Inc Ne COM | $110.0M | 882.4K | 2.8% | ▲+22% Added · +160K sh | |
| 12 | Kalvista Pharmaceuticals Inc COM | $99.9M | 4.96M | 2.6% | ▼−1.6% Reduced · −79K sh | |
| 13 | Disc Medicine Inc COM | $86.6M | 1.35M | 2.2% | ▲+7.5% Added · +95K sh | |
| 14 | Cytokinetics Inc COM NEW | $76.4M | 1.16M | 2.0% | ▲+24% Added · +225K sh | |
| 15 | Revolution Medicines Inc COM | $65.7M | 675.7K | 1.7% | ▼−15% Reduced · −122K sh | |
| 16 | Dyne Therapeutics Inc COM | $57.2M | 3.15M | 1.5% | —Held | |
| 17 | Savara Inc COM | $53.1M | 9.72M | 1.4% | ▼−1.4% Reduced · −141K sh | |
| 18 | Tarsus Pharmaceuticals Inc COM | $51.1M | 728.6K | 1.3% | —Held | |
| 19 | Vor Biopharma Inc COM NEW | $45.4M | 2.54M | 1.2% | —Held | |
| 20 | Agios Pharmaceuticals Inc COM | $42.5M | 1.26M | 1.1% | ▼−1.8% Reduced · −24K sh | |
| 21 | Biocryst Pharmaceuticals Inc COM | $38.2M | 4.01M | 1.0% | ▲New New position | |
| 22 | Zai Lab Ltd ADR | $35.8M | 1.90M | 0.9% | —Held | |
| 23 | Aura Biosciences Inc COM | $34.1M | 5.10M | 0.9% | —Held | |
| 24 | Acadia Pharmaceuticals Inc COM | $32.0M | 1.44M | 0.8% | ▲+11% Added · +141K sh | |
| 25 | Ascendis Pharma A/s SPONSORED ADR | $30.5M | 133.3K | 0.8% | —Held | |
| 26 | Lexeo Therapeutics Inc COM | $25.4M | 4.42M | 0.7% | —Held | |
| 27 | Alkermes PLC SHS | $24.8M | 700.6K | 0.6% | —Held | |
| 28 | Aclaris Therapeutics Inc COM | $18.5M | 4.93M | 0.5% | ▲New New position | |
| 29 | Monte Rosa Therapeutics Inc COM | $16.4M | 1.00M | 0.4% | ▲New New position | |
| 30 | Immunocore Hldgs PLC ADS | $14.6M | 484.8K | 0.4% | ▲+26% Added · +100K sh | |
| 31 | Mannkind Corp COM NEW | $14.5M | 5.90M | 0.4% | ▲+40% Added · +1.7M sh | |
| 32 | Valneva SE SPONSORED ADS | $14.3M | 2.29M | 0.4% | —Held | |
| 33 | Evolus Inc COM | $10.8M | 2.63M | 0.3% | —Held | |
| 34 | Newamsterdam Pharma Company *W EXP 99/99/999 | $10.0M | 500.3K | 0.3% | —Held | |
| 35 | Allogene Therapeutics Inc COM | $9.3M | 3.80M | 0.2% | ▼−1.9% Reduced · −72K sh | |
| 36 | Autolus Therapeutics Ltd SPON ADS | $6.1M | 4.45M | 0.2% | ▼−3.8% Reduced · −175K sh | |
| 37 | Ibio Inc COM NEW | $3.7M | 1.95M | 0.1% | —Held | |
| 38 | Xilio Therapeutics Inc COM | $3.6M | 422.5K | 0.1% | ▲New New position |
As-of date vs the date the SEC received each filing
| Quarter | As of | Filed | Positions | Value | Form |
|---|---|---|---|---|---|
| Q1 2026 | Mar 31, 2026 | May 15, 2026 | 38 | $3.9B | 13F-HR |
| Q4 2025 | Dec 31, 2025 | Feb 13, 2026 | 40 | $3.7B | 13F-HR |
| Q3 2025 | Sep 30, 2025 | Nov 14, 2025 | 47 | $3.3B | 13F-HR |
| Q2 2025 | Jun 30, 2025 | Aug 14, 2025 | 49 | $2.5B | 13F-HR |
| Q1 2025 | Mar 31, 2025 | May 15, 2025 | 47 | $2.2B | 13F-HR |
| Q4 2024 | Dec 31, 2024 | Feb 18, 2025 | 50 | $2.4B | 13F-HR |
| Q3 2024 | Sep 30, 2024 | Nov 15, 2024 | 53 | $2.5B | 13F-HR |
| Q2 2024 | Jun 30, 2024 | Aug 15, 2024 | 49 | $2.1B | 13F-HR |
| Q1 2024 | Mar 31, 2024 | May 15, 2024 | 50 | $2.4B | 13F-HR |
| Q4 2023 | Dec 31, 2023 | Feb 14, 2024 | 49 | $1.9B | 13F-HR |
| Q3 2023 | Sep 30, 2023 | Nov 14, 2023 | 52 | $1.5B | 13F-HR |
| Q2 2023 | Jun 30, 2023 | Aug 14, 2023 | 48 | $1.7B | 13F-HR |
| Q1 2023 | Mar 31, 2023 | May 15, 2023 | 49 | $1.4B | 13F-HR |
| Q4 2022 | Dec 31, 2022 | Feb 7, 2023 | 44 | $1.6B | 13F-HR/A |
| Q3 2022 | Sep 30, 2022 | Nov 14, 2022 | 43 | $1.3B | 13F-HR |
| Q2 2022 | Jun 30, 2022 | Aug 10, 2022 | 41 | $1.1B | 13F-HR |
| Q1 2022 | Mar 31, 2022 | May 16, 2022 | 42 | $1.2B | 13F-HR |
Holdings from SEC EDGAR 13F-HR filings, updated quarterly ~45 days after quarter-end. Public domain. The book and weighting are long equity only; disclosed put/call options are listed separately and excluded from those totals. Price-derived performance is withheld until the price-source policy and freshness gate are green.